Pratima Saini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pratima Saini has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Pires Bonfanti
Laboratory of Immunopatologies, Departament of Microbiology and Immunology, Institute of Biology, Universidade Estadual de Campinas, Campinas 13083-970, Brazil
11 shared publications - Gauri Mirji
The Wistar Institute, Philadelphia, Pennsylvania
11 shared publications - Hiroaki Tateno
Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan
11 shared publications - Hsin-Yao Tang
Proteomics and Metabolomics Facility, Wistar Institute, Philadelphia, PA 19104, USA
11 shared publications - Joel Cassel
The Wistar Institute, Philadelphia, USA
11 shared publications - Judd Franklin Hultquist
Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
11 shared publications
Latest Publications
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Analysis showing expression of human Siglec-10 on myeloid cells in B-hSIGLEC10 mice compared with C57BL/6 controls
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Analysis showing expression of human Siglec-10 on myeloid cells in B-hSIGLEC10 mice compared with C57BL/6 controls
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Sequences of the monoclonal antibodies against Siglec-10
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Sequences of the monoclonal antibodies against Siglec-10
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Flow cytometry analysis showing high expression of ITGA3 and ITGB1 on PDAC cells
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Flow cytometry analysis showing high expression of ITGA3 and ITGB1 on PDAC cells
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Flow cytometry and functional assays showing that ITGA3 knockout reduces Siglec-10 binding and that ITGB1 expression enables PDAC cells to evade macrophage-mediated phagocytosis
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Flow cytometry and functional assays showing that ITGA3 knockout reduces Siglec-10 binding and that ITGB1 expression enables PDAC cells to evade macrophage-mediated phagocytosis
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Flow cytometry analysis showing that anti–Siglec-10 antibodies do not alter ITGA3, ITGB1, or Siglec-10 ligand levels on PDAC cells
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Flow cytometry analysis showing that anti–Siglec-10 antibodies do not alter ITGA3, ITGB1, or Siglec-10 ligand levels on PDAC cells
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Schematic and TCGA dataset analysis showing elevated expression of sialyltransferases that generate Siglec-10 ligands in pancreatic cancer compared to normal tissues
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Schematic and TCGA dataset analysis showing elevated expression of sialyltransferases that generate Siglec-10 ligands in pancreatic cancer compared to normal tissues
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Correlation analysis in TCGA showing associations between ITGA3 or ITGB1 and Siglec-10 and its ligand-forming enzymes (ST3GAL1, B3GNT3)
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Correlation analysis in TCGA showing associations between ITGA3 or ITGB1 and Siglec-10 and its ligand-forming enzymes (ST3GAL1, B3GNT3)
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Tumor-associated macrophages (TAM) in the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) exhibit immunosuppressive phenotypes and impaired phagocytic activity, facilitating tumor progression and immune evasion. In this study, we identified integrin α3β1, composed of ITGA3 and ITGB1 subunits, as a sialylated glycoprotein ligand for Siglec-10, an inhibitory glyco-immune checkpoint receptor highly expressed on TAMs in PDAC. The interaction between Siglec-10 on TAMs and α3β1 on PDAC cells suppressed macrophage-mediated phagocytosis, thereby promoting immune evasion. Consistently, disrupting Siglec-10 interactions using mAbs significantly enhanced macrophage phagocytosis of PDAC cells and alleviated myeloid cell–mediated inhibition of T-cell proliferation and activation in vitro. In both a xenograft mouse model engrafted with human macrophages and a human Siglec-10 transgenic mouse model, targeting Siglec-10 with mAbs reduced PDAC growth. These findings suggest that Siglec-10 interactions are key mediators of TAM-driven immune evasion in PDAC and highlight the therapeutic potential of targeting these interactions to restore antitumor immunity.Significance:Pancreatic tumor cells exploit integrin α3β1 to engage the immunosuppressive checkpoint receptor Siglec-10 on myeloid cells, driving immune evasion, which can be targeted with antibody-mediated blockade of Siglec-10 to restore antitumor immunity.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Tumor-associated macrophages (TAM) in the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) exhibit immunosuppressive phenotypes and impaired phagocytic activity, facilitating tumor progression and immune evasion. In this study, we identified integrin α3β1, composed of ITGA3 and ITGB1 subunits, as a sialylated glycoprotein ligand for Siglec-10, an inhibitory glyco-immune checkpoint receptor highly expressed on TAMs in PDAC. The interaction between Siglec-10 on TAMs and α3β1 on PDAC cells suppressed macrophage-mediated phagocytosis, thereby promoting immune evasion. Consistently, disrupting Siglec-10 interactions using mAbs significantly enhanced macrophage phagocytosis of PDAC cells and alleviated myeloid cell–mediated inhibition of T-cell proliferation and activation in vitro. In both a xenograft mouse model engrafted with human macrophages and a human Siglec-10 transgenic mouse model, targeting Siglec-10 with mAbs reduced PDAC growth. These findings suggest that Siglec-10 interactions are key mediators of TAM-driven immune evasion in PDAC and highlight the therapeutic potential of targeting these interactions to restore antitumor immunity.Significance:Pancreatic tumor cells exploit integrin α3β1 to engage the immunosuppressive checkpoint receptor Siglec-10 on myeloid cells, driving immune evasion, which can be targeted with antibody-mediated blockade of Siglec-10 to restore antitumor immunity.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Flow cytometry analysis showing Siglec-10 expression in monocytes and monocyte-derived macrophages
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Flow cytometry analysis showing Siglec-10 expression in monocytes and monocyte-derived macrophages
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Gating strategy for sorting human tumor-associated macrophages from mouse subcutaneous tumors for RNA-seq analysis
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer
Gating strategy for sorting human tumor-associated macrophages from mouse subcutaneous tumors for RNA-seq analysis